Cingulate Incの株価・株式情報
企業概要
Cingulate is a clinical stage biopharmaceutical company using its key Precision Timed Release drug delivery platform technology to build and develop a pipeline of pharmaceutical products. Co. is initially focusing its efforts on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Co.'s two proprietary stimulant medications: CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), are being developed for the treatment of ADHD, in the three main patient segments: children (ages six t
